K-232 phase 3 long-term administration study

K-232 phase 3 long-term administration study in patients with primary open-angle glaucoma (POAG), exfoliative glaucoma, pigmentary glaucoma or ocular hypertension (OH)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225063

Enrollment

160

Registered

2020-02-13

Start date

2020-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open-angle glaucoma (broad definition), exfoliative glaucoma, pigmentary glaucoma, ocular hypertension

Interventions

investigational material(s) Generic name etc : K-232 INN of investigational material : - Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.POAG (broad definition), exfoliative glaucoma, pigmentary glaucoma or OH patients 2.Baseline IOP => 15mmHg

Exclusion criteria

Exclusion criteria: 1.Patients whose visual acuity is below 0.3 2.Patients with severe visual field defects 3.Patients thought to wear contact lenses etc.

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety :Incidence of adverse event and adverse drug reaction Efficacy :Mean IOP reduction from baseline at all measurement points	—

Secondary

Measure	Time frame
safety efficacy Safety :Change from baseline in ophthalmologic examination at 28 weeks and 52 weeks, etc Efficacy :IOP at all measurement points	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026